A Study Evaluating The Safety And Efficacy Of Daclatasvir (DCV) Plus Sofosbuvir (SOF) Regimens With Or Without Ribavirin (RBV) In Chronic Hepatitis C Virus Infected (HCV) Patients With Advanced Liver Fibrosis And Compensated Or Decompensated Cirrhosis.
Latest Information Update: 30 Jan 2017
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2017 New trial record